Skip to Content

Theranos Is Closing Its Labs and Hemorrhaging Jobs

CEO Elizabeth Holmes finally admits what was obvious all along.
October 6, 2016

The beleaguered blood-testing company Theranos has announced that it will close its testing labs and cut 340 staff from its books.

In an open letter to its stakeholders, the company’s CEO, Elizabeth Holmes, explained that Theranos had spent months “assessing our strengths and addressing … weaknesses.” Its weaknesses, if you didn’t already know, are all the clinical labs and Wellness Centers that it operates, which are now going to close.

Not that Holmes had a great deal of choice. Over the summer, U.S. regulators banned her from operating clinical labs. That decision followed a catastrophic series of problems at the company, which were first brought to light by a Wall Street Journal investigation that alleged its technology didn’t work. Shutting down the facilities, then, was the only way she could realistically continue operating the company.

A sign outside the construction site of Theranos HQ in Silicon Valley, way back in 2014.

Theranos was at one point a darling of Silicon Valley, valued at a dizzying $9 billion. And if its claims had come to fruition, that would have been justified. The company said that its technology, known as Edison, was able to perform an array of blood tests with just a finger-prick of blood.

But those claims didn’t stand up. Its results turned out to deviate from standard blood tests, and investigations showed that the labs were poorly run—the company didn’t even store blood samples at the correct temperature.

Holmes says Theranos will now turn its attention to its so-called MiniLab—a small, Internet-connected device capable of performing an array of blood tests. “Our ultimate goal is to commercialize miniaturized, automated laboratories capable of small-volume sample testing, with an emphasis on vulnerable patient populations, including oncology, pediatrics, and intensive care,” she writes. The device is thought to use a similar approach to the Edison technology that predated it—though, crucially, it won’t require running a lab.

But even if MiniLab is a success, Theranos has a fight on its hands. At this stage, its reputation is in tatters, and Forbes values the company at zero. Its fall from grace could yet cost it more than just its labs.

(Read more: Theranos, “Theranos Promised a Revolution, but Delivered Dangerous Errors,” “Theranos Unveils 'MiniLab' Invention to a Skeptical Audience”)

Keep Reading

Most Popular

A Roomba recorded a woman on the toilet. How did screenshots end up on Facebook?

Robot vacuum companies say your images are safe, but a sprawling global supply chain for data from our devices creates risk.

A startup says it’s begun releasing particles into the atmosphere, in an effort to tweak the climate

Make Sunsets is already attempting to earn revenue for geoengineering, a move likely to provoke widespread criticism.

10 Breakthrough Technologies 2023

Every year, we pick the 10 technologies that matter the most right now. We look for advances that will have a big impact on our lives and break down why they matter.

These exclusive satellite images show that Saudi Arabia’s sci-fi megacity is well underway

Weirdly, any recent work on The Line doesn’t show up on Google Maps. But we got the images anyway.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.